Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Stock Information for Galecto Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Galecto Inc.

Galecto Reports First Quarter 2025 Operating and Financial Results
Galecto Reports Full-Year 2024 Financial Results
Galecto to Participate in Upcoming Investor Conferences
Galecto Reports Third Quarter 2024 Financial Results
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler
Galecto Announces Reverse Stock Split
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.